Japanese firm acquires US drugmaker after increasing offer

The deal sees Sumitomo acquiring ownership of cancer and uterine fibroid treatments | Myovant initially rejected low offer that “undervalued” the company.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Federal Circuit affirms Latuda decision in Sumitomo clash

19 April 2018 The US Court of Appeals for the Federal Circuit affirmed a lower court’s claim construction of a patent which covers Sunovion’s schizophrenia and bipolar depression drug Latuda on Monday, April 16.

Americas

Par Pharmaceutical in pre-emptive strike to protect Latuda generic

5 January 2017 Par Pharmaceutical has sought a declaratory judgment that it did not infringe patents belonging to Sumitomo and its subsidiary Sunovion that protect bipolar disorder drug Latuda.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Japanese firm acquires US drugmaker after increasing offer

More on this story

Editor's picks

Editor's picks

More features